This study enrolls patients with Non-small cell lung cancer and treats them with the investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1). Treating with an antiCLEVER-1 antibody, such as bexmarilimab, could lead to immune system activation, which, in turn, may lead to cancer elimination.

Start Date01 Jun 2023

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

NCT05428969 / RecruitingPhase 1/2

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

Start Date02 Jun 2022

Sponsor / Collaborator

Faron Pharmaceuticals Oy

NCT05104905 / WithdrawnPhase 1/2

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (Macrophage Antibody To Inhibit Immune Suppression in RENAl Cell and COLon Carcinomas)

Bexmarilimab treatment has demonstrated tolerable safety profile and anticancer efficacy in some subjects with advanced malignancies. This is the first study to investigate the effect of single neoadjuvant dose of anti-CLEVER-1 antibody bexmarilimab prior to radical surgery of renal cell and colon cancers. We expect that the single dose will demonstrate measurable effects on the tumour immunological microenvironment as well as systemic effects on subject´s immunological status and that this evidence may be used to guide future neoadjuvant studies. There will be a dose escalation to investigate the effect of different doses of bexmarilimab. In addition to subjects receiving single neoadjuvant dose of bexmarilimab, there will be an observational cohort without Investigational Medicinal Product (IMP) for either cancer. All patients participating in the study (whether in investigational or observational cohort) will attend each visit and are assessed for the same endpoints.

Start Date07 Oct 2021

Sponsor / Collaborator

Faron Pharmaceuticals Oy

100 Clinical Results associated with Bexmarilimab

100 Translational Medicine associated with Bexmarilimab

100 Patents (Medical) associated with Bexmarilimab

Literatures (Medical) associated with Bexmarilimab

03 Jan 2024·Cancer immunology research

Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments

Article

Author: Hynninen, Johanna ; Hollmén, Maija ; Rannikko, Jenna H ; Bono, Petri

Abstract:

Immune checkpoint inhibitors (ICI) show substantially greater efficacy in inflamed tumors characterized by preexisting T-cell infiltration and IFN signaling than in noninflamed “cold” tumors, which often remain immunotherapy resistant. The cancer immunotherapy bexmarilimab, which inhibits the scavenger receptor Clever-1 to release macrophage immunosuppression and activate adaptive immunity, has shown treatment benefit in subsets of patients with advanced solid malignancies. However, the mechanisms that determine bexmarilimab therapy outcome in individual patients are unknown. Here we characterized bexmarilimab response in ovarian cancer ascites macrophages ex vivo using single-cell RNA sequencing and demonstrated increased IFN signaling and CXCL10 secretion following bexmarilimab treatment. We further showed that bexmarilimab was most efficacious in macrophages with low baseline IFN signaling, as chronic IFNγ priming abolished bexmarilimab-induced TNFα release. These results highlight an approach to target immunologically cold tumors and to increase the likelihood of their subsequent response to ICIs.

01 Dec 2023·Cell reports. Medicine

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

Article

Author: Arora, Sukeshi Patel ; Ma, Yuk Ting ; Jalkanen, Juho ; Mandelin, Jami ; Bono, Petri ; Karaman, Sinem ; Skytta, Tanja ; Minchom, Anna ; Xiang, Yujuan ; Iivanainen, Sanna ; Karvonen, Matti K ; Robbrecht, Debbie ; Shetty, Shishir ; de Miguel, Maria ; Hollmén, Maija ; Verlingue, Loic ; Jaakkola, Panu ; Koivunen, Jussi P ; Rannikko, Jenna H ; Pasanen, Annika ; Graham, Donna M ; Yap, Christina

Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 blockade with bexmarilimab in patients with treatment-refractory solid tumors and assesses preliminary anti-tumor efficacy, pharmacodynamics, and immunologic correlates. Bexmarilimab shows no dose-limiting toxicities in part I (n = 30) and no additional safety signals in part II (n = 108). Disease control (DC) rates of 25%-40% are observed in cutaneous melanoma, gastric, hepatocellular, estrogen receptor-positive breast, and biliary tract cancers. DC associates with improved survival in a landmark analysis and correlates with high pre-treatment intratumoral Clever-1 positivity and increasing on-treatment serum interferon γ (IFNγ) levels. Spatial transcriptomics profiling of DC and non-DC tumors demonstrates bexmarilimab-induced macrophage activation and stimulation of IFNγ and T cell receptor signaling selectively in DC patients. These data suggest that bexmarilimab therapy is well tolerated and show that macrophage targeting can promote immune activation and tumor control in late-stage cancer.

01 Apr 2023·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Preclinical Evaluation of⁸⁹Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Article

Author: Li, Xiang-Guo ; Taimen, Pekka ; Palani, Senthil ; Viitanen, Riikka ; Jalkanen, Sirpa ; Oikonen, Vesa ; Hollmén, Maija ; Miner, Maxwell W G ; Roivainen, Anne ; Liljenbäck, Heidi ; Virta, Jenni ; Yatkin, Emrah ; Vugts, Danielle J ; Moisio, Olli ; Tolvanen, Tuula

Bexmarilimab is a new humanized monoclonal antibody against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and is in clinical trials for macrophage-guided cancer immunotherapy. In addition being associated with cancer, CLEVER-1 is also associated with fibrosis. To facilitate prospective human PET studies, we preclinically evaluated ⁸⁹Zr-labeled bexmarilimab in rabbits. Methods: Bexmarilimab was conjugated with desferrioxamine (DFO) and radiolabeled with ⁸⁹Zr. Retained immunoreactivity was confirmed by flow cytometry. The distribution kinetics of intravenously administered ⁸⁹Zr-DFO-bexmarilimab (0.1 mg/kg) were determined for up to 7 d in a rabbit model of renal fibrosis mediated by unilateral ureteric obstruction. The in vivo stability of ⁸⁹Zr-DFO-bexmarilimab was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in combination with autoradiography. Additionally, we estimated the human radiation dose from data obtained in healthy rabbits. Results: ⁸⁹Zr-DFO-bexmarilimab cleared rapidly from the blood circulation and distributed to the liver and spleen. At 24 h after injection, PET/CT, ex vivo γ-counting, and autoradiography demonstrated that there was significantly higher ⁸⁹Zr-DFO-bexmarilimab uptake in unilateral ureteric obstruction-operated fibrotic renal cortex, characterized by abundant CLEVER-1-positive cells, than in contralateral or healthy kidneys. The estimated effective dose for a 70-kg human was 0.70 mSv/MBq. Conclusion: The characteristics of ⁸⁹Zr-DFO-bexmarilimab support future human PET studies to, for example, stratify patients for bexmarilimab treatment, evaluate the efficacy of treatment, or monitor disease progression.

News (Medical) associated with Bexmarilimab

16 May 2024

·www.globenewswire.com

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office AwardsNominated in recognition of research developing bexmarilimab, an investigational immunotherapy optimising clinical outcomes in cancer treatmentVoting now open for “Popular Prize” award ahead of ceremony on July 9 via dedicated link: Sirpa Jalkanen and Markku Jalkanen | Epo.org TURKU, Finland and BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces the nomination of its co-founders, Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, as finalists in the ‘SMEs’ category of the European Inventor Award 2024. Dr. Markku Jalkanen, co-founder, Board member and former CEO of Faron, and Dr. Sirpa Jalkanen, co-founder and member of Faron’s Scientific Advisory Board, have been nominated in recognition of their research developing Faron’s wholly owned precision cancer immunotherapy candidate, bexmarilimab. One of the most advanced myeloid cell-targeting immunotherapy candidates in development, bexmarilimab is designed to target the Clever-1 receptor present on macrophages, activating anti-tumor immunity in hematological and solid tumor microenvironments to overcome resistance and provide better patient outcomes. Bexmarilimab is currently being investigated in the ongoing BEXMAB trial, evaluating the candidate’s safety and efficacy in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS), an aggressive myeloid leukemia with very few treatment options. In addition, every year, the public can vote for their favorite inventor: the Popular Prize goes to the shortlisted inventor with the most votes. The winners in each category, and the winner of the Popular Prize, will be announced at the online award ceremony on 9 July 2024. For further information and to vote for the Popular Prize, visit: Sirpa Jalkanen and Markku Jalkanen | Epo.org Dr. Markku Jalkanen, Board member and former CEO of Faron, said: “It is an honor to be recognized by the European Patent Office and nominated for this prestigious award. The continued progress of our ambitious bexmarilimab development program and the exceptional data we are seeing in the ongoing Phase I/II BEXMAB trial, reaffirms our belief in the potential of bexmarilimab to change the treatment paradigm. These highly significant findings provide us with continued confidence that bexmarilimab can improve the quality of life of those suffering from these aggressive hematological cancers, where there are limited options available for future therapy.” Launched by the European Patent Office in 2006, the European Inventor Award is one of Europe’s most renowned innovation prizes. This award recognizes people behind successful inventions in small and medium-sized enterprises (SMEs) and honors individuals who transform their ideas into solutions to address some of the biggest challenges of our time. For more information please contact: Faron PharmaceuticalsInvestor ContactLifeSci AdvisorsDaniel FerryManaging Directordaniel@lifesciadvisors.com+1 (617) 430-7576 ICR ConsiliumMary-Jane Elliott, David Daley, Lindsey NevillePhone: +44 (0)20 3709 5700E-mail: faron@consilium-comms.com Cairn Financial Advisers LLP, NomadSandy Jamieson, Jo TurnerPhone: +44 (0) 207 213 0880 Peel Hunt LLP, BrokerChristopher Golden, James SteelPhone: +44 (0) 20 7418 8900 Sisu Partners Oy, Certified Adviser on Nasdaq First NorthJuha KarttunenPhone: +358 (0)40 555 4727Jukka JärveläPhone: +358 (0)50 553 8990 About Faron Pharmaceuticals Oy Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com. About BEXMABThe BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes. About BexmarilimabBexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

ImmunotherapyClinical Study

16 Apr 2024

·www.globenewswire.com

Faron Confirms Plans for the Coming Months Under New Leadership

Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next monthIncoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024. Initial data from the ongoing Phase 2 part of the BEXMAB trial, evaluating the safety and efficacy of bexmarilimab in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS), is expected to be announced during the week commencing 20 May 2024. This data readout will be important for ongoing partnering discussions and the major upcoming industry events that Faron will be attending, including the American Society for Clinical Oncology (ASCO) annual meeting and the Bio International Convention, taking place in June 2024. Given the promising data already seen in the Phase 1 part of the trial, among HMA-failed MDS patients who have no approved treatment options, the Company plans to approach the US Food and Drug Administration (FDA) earlier than planned this year, seeking a Scientific Advice meeting regarding its registrational study plan, in order to coordinate and finalize plans that may lead to marketing approval. “2024 is set to be a pivotal year for Faron in the delivery of key milestones that will be critical to the further development of bexmarilimab,” said Dr. Juho Jalkanen, Faron’s incoming Chief Executive Officer. “In my new role as CEO, I am excited to start executing on some of these key activities and accelerating important discussions with the FDA as we map our future plans for bexmarilimab together. There is a tremendous need for an effective treatment in HMA-failed MDS patients, and so we are very keen to ensure we get this treatment option to patients as soon as we can.” For more information please contact: Faron PharmaceuticalsInvestor ContactLifeSci AdvisorsDaniel FerryManaging Directordaniel@lifesciadvisors.com+1 (617) 430-7576 ICR ConsiliumMary-Jane Elliott, David Daley, Lindsey NevillePhone: +44 (0)20 3709 5700E-mail: faron@consilium-comms.com Cairn Financial Advisers LLP, NomadSandy Jamieson, Jo TurnerPhone: +44 (0) 207 213 0880 Peel Hunt LLP, BrokerChristopher Golden, James SteelPhone: +44 (0) 20 7418 8900 Sisu Partners Oy, Certified Adviser on Nasdaq First NorthJuha KarttunenPhone: +358 (0)40 555 4727Jukka JärveläPhone: +358 (0)50 553 8990 About Faron Pharmaceuticals Oy Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.

Phase 2Executive ChangeImmunotherapyASCO

16 Apr 2024

·www.biospace.com

Faron Confirms Plans for the Coming Months Under New Leadership - April 16, 2024

Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next month Incoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024. Initial data from the ongoing Phase 2 part of the BEXMAB trial, evaluating the safety and efficacy of bexmarilimab in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS), is expected to be announced during the week commencing 20 May 2024. This data readout will be important for ongoing partnering discussions and the major upcoming industry events that Faron will be attending, including the American Society for Clinical Oncology (ASCO) annual meeting and the Bio International Convention, taking place in June 2024. Given the promising data already seen in the Phase 1 part of the trial, among HMA-failed MDS patients who have no approved treatment options, the Company plans to approach the US Food and Drug Administration (FDA) earlier than planned this year, seeking a Scientific Advice meeting regarding its registrational study plan, in order to coordinate and finalize plans that may lead to marketing approval. “2024 is set to be a pivotal year for Faron in the delivery of key milestones that will be critical to the further development of bexmarilimab,” said Dr. Juho Jalkanen, Faron’s incoming Chief Executive Officer. “In my new role as CEO, I am excited to start executing on some of these key activities and accelerating important discussions with the FDA as we map our future plans for bexmarilimab together. There is a tremendous need for an effective treatment in HMA-failed MDS patients, and so we are very keen to ensure we get this treatment option to patients as soon as we can.” For more information please contact: Faron Pharmaceuticals Investor Contact LifeSci Advisors Daniel Ferry Managing Director daniel@lifesciadvisors.com +1 (617) 430-7576 ICR Consilium Mary-Jane Elliott, David Daley, Lindsey Neville Phone: +44 (0)20 3709 5700 E-mail: faron@consilium-comms.com Cairn Financial Advisers LLP, Nomad Sandy Jamieson, Jo Turner Phone: +44 (0) 207 213 0880 Peel Hunt LLP, Broker Christopher Golden, James Steel Phone: +44 (0) 20 7418 8900 Sisu Partners Oy, Certified Adviser on Nasdaq First North Juha Karttunen Phone: +358 (0)40 555 4727 Jukka Järvelä Phone: +358 (0)50 553 8990 About Faron Pharmaceuticals Oy Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at .

Phase 2Executive ChangeImmunotherapyASCO

100 Deals associated with Bexmarilimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16383

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Myelomonocytic Leukemia	Phase 2	US	Faron Pharmaceuticals Oy	02 Jun 2022
Chronic Myelomonocytic Leukemia	Phase 2	FI	Faron Pharmaceuticals Oy	02 Jun 2022
Refractory acute myeloid leukemia	Phase 2	US	Faron Pharmaceuticals Oy	02 Jun 2022
Refractory acute myeloid leukemia	Phase 2	FI	Faron Pharmaceuticals Oy	02 Jun 2022
Colonic Cancer	Phase 2	FI	Faron Pharmaceuticals Oy	07 Oct 2021
Renal Cell Carcinoma	Phase 2	FI	Faron Pharmaceuticals Oy	07 Oct 2021
Myelodysplastic Syndromes	Phase 2	FI	Faron Pharmaceuticals Oy	08 Sep 2021
Advanced Malignant Solid Neoplasm	Phase 2	US	Faron Pharmaceuticals Oy	03 Dec 2018
Advanced Malignant Solid Neoplasm	Phase 2	FI	Faron Pharmaceuticals Oy	03 Dec 2018
Advanced Malignant Solid Neoplasm	Phase 2	FR	Faron Pharmaceuticals Oy	03 Dec 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05428969 (BEXMAB, Biospace) Manual	Phase 1	Myeloid Leukemia Second line \| First line TP53 Mutation	28	bexmarilimab + azacitidine	skssldgyno(mziyfotbrv) = nqfjuuvinn iancuawqar (lkfzkaisiy )	Positive	11 Dec 2023
				bexmarilimab + azacitidine (previously HMA-failed)	skssldgyno(mziyfotbrv) = rqtoishjwi iancuawqar (lkfzkaisiy )
NCT03733990 (MATINS, SITC2023)	Phase 1/2	Advanced Malignant Solid Neoplasm Clever-1 \| IFNg \| proinflammatory cytokines ... View more	-	Bexmarilimab (FP-1305, Bex)	cokqysbkkc(nlqlawogto) = tcwqrfjjli lmzvgozevn (tferdcglxn )	-	02 Nov 2023
NCT03733990 (MATINS, ESMO2023)	Phase 1/2	Refractory Malignant Solid Neoplasm	216	Bexmarilimab	fwhdpohvtt(ntwsenjxau) = 15.9% of the patients experiencing grade 3-4 TRAE ojtjzabjqu (afugdthsjw ) View more	Positive	23 Oct 2023
NCT05428969 (BEXMAB, GlobeNewswire) Manual	Phase 1/2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	22	Bexmarilimab+standard of care	mxnxvenzjf(cvfgsgtzai) = jmjcsprqjh lgkgmnfjqa (mdrvyrpxqe ) View more	Positive	11 Oct 2023
				Bexmarilimab+standard of care (HMA-failed MDS patients)	mxnxvenzjf(cvfgsgtzai) = yuaqtgihjs lgkgmnfjqa (mdrvyrpxqe )
NCT05428969 (BEXMAB, GlobeNewswire) Manual	Phase 1/2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	21	Bexmarilimab+Azacitidine	rgocrbvkrf(kvvnjnbslq) = cyhfxzixzl vewzvfguzm (fgpcslplvr )	Positive	19 Jul 2023
				Bexmarilimab+Azacitidine+Venetoclax	rgocrbvkrf(kvvnjnbslq) = igcobuzixn vewzvfguzm (fgpcslplvr )
NCT03733990 (MATINS, AACR2022)	Phase 1/2	Advanced Malignant Solid Neoplasm	30	bexmarilimab (Patients with low IFNg and TNFa levels)	(kfamjsgsli) = bgbivziyfr gxpklbcieq (nnlxekqftx, +/ - 4.99) View more	-	15 Jun 2022
				bexmarilimab (Patients with high IFNg and TNFa levels)	(kfamjsgsli) = ejzvxnturc gxpklbcieq (nnlxekqftx, +/ - 13.26) View more
NCT03733990 (MATINS, ASCO2022) Manual	Phase 1/2	Advanced cancer	193	bexmarilimab	zsoiembuie(hdysjbjdwv) = pfrolgalfp piqtmihouv (imjqeiqmdi, 1.9 - 2.0) View more	Positive	02 Jun 2022
NCT03733990 (MATINS, ESMO2021) Manual	Phase 1/2	Solid tumor Last line	159	Bexmarilimab (Part II: 0.3 – 3.0 mg/kg)	irhnasqrqm(qwtfhkpura) = ivcpfzxnsm easngohtwt (gaddkrczak )	Positive	17 Sep 2021
				Bexmarilimab	jyelwhzdud(hqggmituzs) = vmajwkupxy vezoqursvo (frxzoduiws ) View more
NCT03733990 (MATINS, ESMO2020)	Phase 1/2	Advanced cancer	30	FP-1305	bkibayoryp(opuxicmdkt) = 28.9 % of the treatment emergent adverse events were related to the study drug noitkuiqqv (eauynycnuk )	Positive	18 Sep 2020
NCT03733990 (MATINS, ESMO2019)	Phase 1/2	HR-positive/HER2-low Solid Tumors	11	FP-1305 0.3 mg/kg	fudfwhrvwn(hlmbzdrawk) = skbtbdjvjt ckqaqreobf (yafskmfrzv ) View more	-	28 Sep 2019
				FP-1305 1.0 mg/kg	fudfwhrvwn(hlmbzdrawk) = vgrhsquvkz ckqaqreobf (yafskmfrzv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis